NeuroSearch's financial calendar for 2009 is as follows:
4 March 2009: Annual Report 2008
29 April 2009: Annual General Meeting and first quarter report 2009
26 August 2009: Half year report 2009
11 November 2009: Third quarter report 2009
Thomas Hofman-Bang
Chairman of the Board
Contacts:
Flemming Pedersen, CEO, telephone: +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate
Communications, telephone: +45 4017 5103
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq
OMX Copenhagen. The company's core business covers the development of novel
drugs, based on a broad and well-established drug discovery platform focusing on
ion channels and CNS disorders. A substantial share of its activities is partner
financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations
with, among others, Abbott and Astellas. NeuroSearch's drug pipeline comprises
14 clinical (Phase I-III) development programmes: ACR16 for Huntington's disease
(Phase III), tesofensine for obesity and in Type 2 diabetes (prepared for Phase
III), NS2359 for depression (Phase II) and ADHD (Phase II) in partnership with
GSK, ABT-894 for ADHD (Phase II) and pain (Phase II) in partnership with Abbott,
ACR16 for schizophrenia (Phase I) in partnership with Astellas, ACR325 for
Parkinson's disease (Phase II in preparation) and bipolar disorder (Phase II in
preparation), ABT-107 and ABT-560 for the treatment of various CNS disorders -
both (Phase I) in collaboration with Abbott, NSD-644 for pain (Phase I) in
partnership with GSK, ACR343 for Parkinson's disease (Phase I) and NSD-788 for
anxiety/depression (Phase I). In addition, NeuroSearch has a broad portfolio of
preclinical drug candidates and holds equity interests in several biotech
companies.
